Roundview Capital’s Gilead Sciences GILD Stock Holding History

Roundview Capital’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-8,934	Closed	-$724K	–	229
2017 Q3	$724K	Buy	+8,934	New	+$683K	0.21%	125
2017 Q2	–	Sell	-9,611	Closed	-$653K	–	218
2017 Q1	$653K	Sell	9,611 -1,440	-13%	-$101K	0.2%	129
2016 Q4	$791K	Sell	11,051 -7,185	-39%	-$534K	0.25%	109
2016 Q3	$1.44M	Sell	18,236 -625	-3%	-$50.8K	0.51%	59
2016 Q2	$1.57M	Sell	18,861 -50	-0.3%	-$4.44K	0.58%	57
2016 Q1	$1.74M	Sell	18,911 -250	-1%	-$22.5K	0.65%	49
2015 Q4	$1.94M	Hold	19,161	–	–	0.77%	39
2015 Q3	$1.88M	Buy	19,161 +50	+0.3%	+$5.55K	0.81%	33
2015 Q2	$2.24M	Sell	19,111 -50	-0.3%	-$5.46K	0.84%	32
2015 Q1	$1.88M	Buy	19,161 +777	+4%	+$78.9K	0.74%	39
2014 Q4	$1.73M	Buy	+18,384	New	+$1.9M	0.71%	45
2014 Q3	–	Sell	-17,084	Closed	-$1.42M	–	135
2014 Q2	$1.42M	Buy	+17,084	New	+$1.33M	0.57%	62

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Roundview Capital's GILD Position: Q4 2017 in Review

Roundview Capital sold out of Gilead Sciences (GILD) in Q4 2017, closing a stake of 8,934 shares — an estimated $724K sold.

Roundview Capital first reported a position in GILD in Q2 2014 and held it in 12 quarters. The position peaked at $2.24M in Q2 2015. 1,574 funds tracked by Wall St. Rank hold GILD as of Q4 2017.

Roundview Capital reported no remaining Gilead Sciences position as of Q4 2017 after selling out during the quarter.
Roundview Capital sold 8,934 Gilead Sciences shares in Q4 2017, an estimated $724K.
Roundview Capital first reported a position in Gilead Sciences in Q2 2014 and held it in 12 quarters.
Roundview Capital's Gilead Sciences position peaked at $2.24M in Q2 2015.
1,574 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2017.

Based on Roundview Capital's 13F filing for Q4 2017, filed 7 Feb 2018.